BioPharma Resources

Drug Trial Radar · NCT07744113

An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 10 years, up to 17 years

Summary

As written by the sponsor on the registry.

To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.

Conditions

  • Bipolar 1 Disorder
  • Schizophrenia Disorder

Interventions

  • OLZ/SAMDrug

    OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day , 5 mg/day, or 15mg/ day with a maximum daily dose of 20mg/day. The dose of samidorphan will be 10 mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigator Site

    Miami, Florida · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.